ARTICLE
- The Economist
(2023)
A flurry of deals suggests that drug firms favour buying their way out of trouble. Will face competition from cheaper copycats once key patents expire in 2028 in America and Europe two years later | Business
Visibility: Public (all visitors)
Comments
Related Chunks
Related chunks with this resource
A collection of articles and videos looking at Prescription Drugs and Big Pharma industry in the USA
No comments yet. Be the first to comment!